Modality
Gene Editing
MOA
Anti-Aβ
Target
Cl18.2
Pathway
T-cell
ETHeart FailureCeliac
Development Pipeline
Preclinical
~Feb 2012
→ ~May 2013
Phase 1
~Aug 2013
→ ~Nov 2014
Phase 2
~Feb 2015
→ ~May 2016
Phase 3
~Aug 2016
→ ~Nov 2017
NDA/BLA
~Feb 2018
→ ~May 2019
Approved
Aug 2019
→ Mar 2031
ApprovedCurrent
NCT07476423
1,066 pts·ET
2019-08→2031-03·Terminated
1,066 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-03-155.0y awayPh3 Readout· ET
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Termina…
Catalysts
Ph3 Readout
2031-03-15 · 5.0y away
ET
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07476423 | Approved | ET | Terminated | 1066 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP |